Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: A randomized open label trial
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: The aim of this study was to investigate the potential use of mirtazapine in Korean veterans diagnosed with PTSD, by comparing it with sertraline, a drug approved for use in PTSD in the USA. Methods: Efficacy was evaluated by the clinician administered PTSD scale (CAPS‐2), the Hamilton rating scale for depression (HAMD‐17) and the clinical global impression scale (CGI), at baseline and at weeks 1, 2 and 6. A response was defined as a ≥ 30 % decrease in CAPS‐2 total severity, a ≥ 50 % decrease in total HAMD‐17 score, and a CGI‐I score < 3. Results: 51 patients on mirtazapine (mean age/duration of illness: 59.1/33.5 years) and 49 on sertraline (mean age/duration of illness: 60.6/35.6 years) completed the study. The mean daily dosage was 34.1 mg for mirtazapine and 101.5 mg for sertraline. On the CAPS‐2 total score more patients responded in the mirtazapine group at week 1 (13 vs 2 %) and week 2 (51 vs 31 %). At week 6 this difference was statistically significant (88 % vs 69 %, p = 0.039) on the CAPS‐2 total score. The HAMD‐17 total score and CGI‐I score decreased in both groups, with no significant differences between th groups on all time points. The main side effects for the mirtazapine group were: dry mouth (19.6 %), constipation (19.6 %), somnolence (15.7 %) and weight gain (1.96 %); and for the sertraline group: indigestion (14.3 %), palpitation (6.1 %), agitation (2.0 %), epigastric soreness (2.0 %), insomnia (2.0 %) and sexual dysfunction (2.0 %). Conclusion: Mirtazapine appeared to be an effective and well‐tolerated treatment for PTSD in Korean veterans. Copyright © 2004 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mirtazapine Versus Venlafaxine in Hospitalized Severely Depressed Patients With Melancholic Features
Guelfi, J. D., Ansseau, M., Timmerman, L., & Kørsgaard, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00010 · Cited by 138
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“trial, response rates were significantly higher with mirtazapine than sertraline [1001].”
BackgroundInfluentialBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“, 2006); and mirtazapine had somewhat greater than effectiveness than sertraline, in a randomised but ‘open’ trial [II] (Chung et al., 2004).”
BackgroundResultPharmacotherapy for post traumatic stress disorder (PTSD)
Stein, D. J., Ipser, J. C., Seedat, S., Sager, C., & Amos, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub2 · Cited by 519
Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis
Hoskins, M., Pearce, J., Bethell, A., Dankova, L., Barbui, C., Tol, W. A., van Ommeren, M., de Jong, J., Seedat, S., Chen, H., et al. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.148551 · Cited by 418
Coventry, P. A., Meader, N., Melton, H., Temple, M., Dale, H., Wright, K., Cloitre, M., Karatzias, T., Bisson, J., Roberts, N. P., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003262 · Cited by 358
“Two other studies were head-to-head comparisons of paroxetine with amitriptyline [35] and of mirtazapine with sertraline [37].”
BackgroundForbes, D., Creamer, M., Phelps, A., Bryant, R., McFarlane, A., Devilly, G. J., Matthews, L., Raphael, B., Doran, C., Merlin, T., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701449161 · Cited by 335
A lifespan view of anxiety disorders
Lenze, E. J., & Wetherell, J. L. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/elenze · Cited by 227
Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders
Croom, K. F., Perry, C. M., & Plosker, G. L. (2009) · CNS Drugs · doi:10.2165/00023210-200923050-00006 · Cited by 158
Sleep and Antidepressant Treatment
Wichniak, A., Wierzbicka, A., & Jernajczyk, W. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523608 · Cited by 142
Buhmann, C. B., Nordentoft, M., Ekstroem, M., Carlsson, J., & Mortensen, E. L. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.150961 · Cited by 92
A Review of Therapeutic Uses of Mirtazapine in Psychiatric and Medical Conditions
Alam, A., Voronovich, Z., & Carley, J. A. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13r01525 · Cited by 84
Bajor, L. A., Ticlea, A. N., & Osser, D. N. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.614483 · Cited by 76
Review of the use of mirtazapine in the treatment of depression
Benjamin, S., & Doraiswamy, P. M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.585459 · Cited by 46
Bajor, L. A., Balsara, C., & Osser, D. N. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114840 · Cited by 43
Genome to Phenome: A Systems Biology Approach to PTSD Using an Animal Model
Chakraborty, N., Meyerhoff, J., Jett, M., & Hammamieh, R. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6952-4_6 · Cited by 14
Metadata
- Authors
- Chung, M. Y., Min, K. H., Jun, Y. J., Kim, S. S., Kim, W. C., & Jun, E. M.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2004-08-09
- Volume
- 19
- Issue
- 7
- Pages
- 489-494
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2139206480
- Cited by
- 92
- References
- 1
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.